文献速递心境障碍

抑郁症药物基因组学临床支持工具的循证更新

Pharmacogenomic Clinical Support Tools for the Treatment of Depression.
PubMed 文献 · Am J Psychiatry · 2024-04-30

仅3项试验(27%)在主要结局上显示统计学显著疗效,且研究设计存在未完全设盲等局限。结论认为新数据未改变2018年建议及FDA观点,即证据不支持使用现有组合PGx工具指导重性抑郁障碍的治疗选择。

要点

  • 新证据未改变2018年建议:不推荐用现有组合PGx工具选择抑郁症治疗。
  • 仅27%新试验在主要结局显示显著疗效,45%未检测到显著疗效。
  • 所有研究均未采用完全设盲设计,仅2项尝试对治疗医生设盲。

核心结论

  • 新数据未改变2018年报告的建议及FDA观点,即证据不支持使用现有组合PGx工具进行重性抑郁障碍的治疗选择。

研究设计与样本

  • 综述更新了美国精神病学协会研究委员会生物标志物与新型治疗工作组2018年立场声明,检索2017至2022年发表的PGx工具用于抑郁症治疗选择的新临床试验和荟萃分析。

主要发现

  • 3项试验(27%)在主要结局指标上显示统计学显著疗效,分别使用不同PGx工具,其中1项为开放标签,另2项为小型单盲试验。
  • 5项试验(45%)在主要或次要结局指标上均未检测到统计学显著疗效。
  • 仅1项试验(9%)以不良事件作为主要结局指标。
  • 所有研究均有显著局限性,例如无一采用完全设盲设计,仅2项研究尝试对治疗医生设盲,且无研究纳入盲法有效性评估或非盲对结果影响的评估。

关键数值与推荐

  • 3项试验(27%)主要结局达统计学显著疗效。
  • 5项试验(45%)主要或次要结局均未达统计学显著疗效。
  • 1项试验(9%)以不良事件为主要结局。
  • 仅2项研究尝试对治疗医生设盲。

临床怎么用

  • 临床不应将现有组合PGx工具用于重性抑郁障碍的治疗选择。
  • 未来研究应优先采用完全设盲设计,纳入当前商业检测未包含的有前景遗传变异,并探索PGx用于估计罕见药物不良反应的可能性而非提高疗效速度或幅度。

局限性

  • 所有纳入研究均有显著局限性,无一采用完全设盲设计,仅2项尝试对治疗医生设盲。
  • 无研究评估盲法有效性或非盲对研究结果的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In this review, the authors update the 2018 position statement of the American Psychiatric Association Council of Research Workgroup on Biomarkers and Novel Treatments on pharmacogenomic (PGx) tools for treatment selection in depression. METHODS: The literature was reviewed for new clinical trials and meta-analyses, published from 2017 to 2022, of studies using PGx tools for treatment selection in depression. The blinding and control conditions, as well as primary and secondary outcomes and post hoc analyses, were summarized. RESULTS: Eleven new clinical trials and five meta-analyses were identified; all studies had primary outcome measures related to speed or efficacy of treatment response. Three trials (27%) demonstrated efficacy on the primary outcome measure with statistical significance; the three studies used different PGx tools; one study was open-label and the other two were small single-blind trials. Five trials (45%) did not detect efficacy with statistical significance on either primary or secondary outcome measures. Only one trial (9%) used adverse events as a primary outcome measure. All studies had significant limitations; for example, none adopted a fully blinded study design, only two studies attempted to blind the treating clinician, and none incorporated measures to estimate the effectiveness of the blinds or the influence of lack of blinding on the study results. CONCLUSIONS: The addition of these new data do not alter the recommendations of the 2018 report, or the advice of the U.S. Food and Drug Administration, that the evidence does not support the use of currently available combinatorial PGx tools for treatment selection in major depressive disorder. Priority efforts for future studies and the development and testing of effective tools include fully blinded study designs, inclusion of promising genetic variants not currently included in any commercially available tests, and investigation of other uses of pharmacogenomics, such as estimating the likelihood of rare adverse drug effects, rather than increasing the speed or magnitude of drug response.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Baum ML, Widge AS, Carpenter LL, et al. Pharmacogenomic Clinical Support Tools for the Treatment of Depression. Am J Psychiatry. 2024. PMID: 38685859. doi:10.1176/appi.ajp.20230657

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。